stockportfolio.pro
ENSG vs HALO: Which Stock Is the Better Buy?
The Ensign Group, Inc. and Halozyme Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ENSG vs HALO, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| The Ensign Group, Inc. (ENSG) | Halozyme Therapeutics, Inc. (HALO) | |
|---|---|---|
| Market cap | $8.9B | $8.4B |
| Revenue (latest FY) | $5.06B | $1.40B |
| Net income (latest FY) | $343.97M | $316.89M |
| Revenue growth (5y CAGR) | 16.1% | 39.2% |
| Net margin | 6.8% | 22.7% |
| Return on equity | 15.4% | 649.2% |
| P/E ratio | 24.6 | 24.9 |
| Dividend yield | 0.2% | — |
| Profitable years (of last 10) | 10 | 7 |
| Positive free cash flow | — | Yes |
See the full ENSG vs HALO breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ENSG's full financials → Open HALO's full financials →More comparisons
Frequently asked questions
Which is bigger, ENSG or HALO?
The Ensign Group, Inc. is larger by market capitalization — $8.9B versus $8.4B.
Which grows faster, ENSG or HALO?
Over the last five fiscal years, Halozyme Therapeutics, Inc. grew revenue faster — 39.2%/yr versus 16.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.